2024
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Wiseman A, Alhamad T, Alloway R, Concepcion B, Cooper M, Formica R, Klein C, Kumar V, Leca N, Shihab F, Taber D, Mulnick S, Bushnell D, Hadi M, Bunnapradist S. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Annals Of Transplantation 2024, 29: e943498-1-e943498-13. PMID: 38526543, PMCID: PMC10944009, DOI: 10.12659/aot.943498.Peer-Reviewed Original ResearchConceptsLCP-tacrolimusImmediate-release tacrolimusKidney transplantationFirst-line optionKidney transplant recipientsRandomized clinical trialsDe novo settingTacrolimus formulationReview available dataEvidence-based recommendationsTrough levelsOnce-dailyTransplant recipientsClinical decision-makingOptimal doseClinical trialsExpert cliniciansConsensus statementTransplant expertsStrength of evidenceClinical practiceKidneyTacrolimusDe novoDelphi consensus survey
2018
Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes
Faddoul G, Nadkarni GN, Bridges ND, Goebel J, Hricik DE, Formica R, Menon MC, Morrison Y, Murphy B, Newell K, Nickerson P, Poggio ED, Rush D, Heeger PS. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. Transplantation 2018, 102: 673-680. PMID: 29189482, PMCID: PMC6018026, DOI: 10.1097/tp.0000000000002026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersChemokine CXCL9Enzyme-Linked Immunospot AssayFemaleGlomerular Filtration RateGraft RejectionGraft SurvivalHumansInterferon-gammaInterferon-gamma Release TestsKidneyKidney TransplantationMaleMiddle AgedNorth AmericaPredictive Value of TestsProspective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsEnzyme-linked immunosorbent spotGraft lossAcute cellular rejectionKidney allograft lossKidney transplant outcomesGlomerular filtration rateMultivariable logistic regressionAllograft lossCellular rejectionCXCL9 levelsUrinary CXCL9Year posttransplantTransplant outcomesImmunosorbent spotUnivariable analysisChemokine measurementsFiltration rateSurrogate markerClinical trialsLate outcomesOrgan transplantationT cellsInterferon gammaAnalysis of biomarkersLogistic regressionSolid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients
Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Current Opinion In Organ Transplantation 2018, 23: 257-263. PMID: 29432255, DOI: 10.1097/mot.0000000000000504.Peer-Reviewed Original ResearchConceptsViremic donorsHepatitis CWaitlist mortalityHepatitis C viremic donorsEarly trial dataHCV-negative recipientsTransplantation of graftsHepatitis C therapySolid organ transplantsSolid organ transplantationUtilization of graftsFormal clinical trialsNet overall reductionGraft utilizationNonviremic recipientsTransplant recipientsC therapyNegative patientsAntiviral therapyNegative recipientsTransplantation ratesClinical trialsOrgan poolDonor organsOrgan transplantation
2013
Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury
Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild RL, Riggs M, Spain K, Ikle D, Bridges ND, Heeger PS, consortium F. Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury. American Journal Of Transplantation 2013, 13: 2634-2644. PMID: 23968332, PMCID: PMC3959786, DOI: 10.1111/ajt.12426.Peer-Reviewed Original ResearchConceptsAcute rejectionUrinary CXCL9Kidney transplantationBiopsy-proven acute rejectionFirst kidney transplant recipientsKidney transplant injuryProgressive renal dysfunctionKidney transplant recipientsMulticenter observational studyGlomerular filtration rateAcute dysfunctionAllograft recipientsCXCL9 mRNAImmunological causesRenal dysfunctionTransplant recipientsImmune injuryTransplant injuryImmune riskUrinary mRNAFiltration rateClinical trialsObservational studyLower riskNoninvasive biomarkers
2002
Evolving role of sirolimus immunosuppression after organ transplantation
Formica R, Friedman A, Lorber M. Evolving role of sirolimus immunosuppression after organ transplantation. Current Opinion In Organ Transplantation 2002, 7: 353-358. DOI: 10.1097/00075200-200212000-00009.Peer-Reviewed Original ResearchCalcineurin inhibitorsOrgan transplantationG1-S phase cell cycle arrestHigher serum creatinine valuesBiologic side effectsSirolimus-treated patientsCalcineurin inhibitor tacrolimusSerum creatinine valuesPivotal clinical trialsReduced rejection ratesPhase cell cycle arrestAllograft arteriosclerosisSirolimus immunosuppressionTriglyceride elevationLymphocele formationSirolimus useReversible thrombocytopeniaSerum cholesterolCreatinine valuesCell cycle arrestClinical trialsSide effectsSirolimusComplex woundsFull dose